Verified email-pattern data for Vaxican is currently limited. You can still use the company insights and contact sections below.
VAXiCAN, pre-clinical stage biotechnology company with vision to create Next Generation Immunotherapeutics, develops unique novel platform of therapeutic cancer vaccines based on proprietary enveloped virus-like particles (Enveloped VLPs), which provide the safest and most effective way of instructing and strengthening the Patient's anticancer defense mechanisms.
VAXiCAN VLP platform is widely supported by fully owned and in-house developed novel dedicated proprietary elements of machine learning (ML) and artificial intelligence (AI).
The path chosen by the VAXiCAN is the use of naturally occurring or genetically modified oncolytic viruses using an innovative antigen delivery method using insect models (most similar solutions use mammalian, fungal or completely synthetic models).
VAXiCAN VLP vaccines are designed to present the extracellular domains of cancer antigens while leveraging the immune system's mechanism to mimic viral infection, thereby enhancing antigen presentation through the recognition of pathogen-associated molecular patterns (PAMPs). This strategy not only stimulates a strong adaptive immune response characterized by the production of high-affinity antibodies and cytotoxic T cells crucial for targeting tumor cells, but also actively engages natural killer cells supported by memory cells.
First pre-clinical lead candidates are addressing HER2 and GD2 cancers, incl. breast cancer, neuroblastoma, melanoma as well as HPV/HBV-related cancers with potential of at least two first-in-class drug candidates and at least one in the orphan drug and fast track regulatory designations.
VAXiCAN also operates in the field of modern whole viral and protein sequencing acting as Oxford Nanopore certified partner. We specialize in bioinformatic analysis of full genomes of microorganisms, including bacteria, bacteriophages, human and animal viruses as well as full human genomes.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Gdansk, Pl
- Industry
- Biotechnology Research
- Website
- https://vaxican.com
- Keywords
- biotechnology, cancer vaccines, immunotherapeutics, breast cancer, melanoma, neuroblastoma, HPV, Covid, Genomic, NGS, Oxford Nanopore, vaccines, Preventive vaccines, VLP.
- HQ
- Gdansk
Vaxican Questions
VAXiCAN's website is https://vaxican.com
VAXiCAN's LinkedIn profile is https://pl.linkedin.com/company/vaxican
VAXiCAN has
5 employees.
View email and phone details for 5
employees at VAXiCAN.
VAXiCAN's industry is
Biotechnology Research
VAXiCAN's top competitors are
Lek-Am,
Cellis,
Ryvu Therapeutics,
Nanogroup S.a.,
Intodna,
Poltreg S.a.,
Explorna Therapeutics,
Tg Pharma - Demophta,
Wpd Pharmaceuticals Sp. Z O.o.,
Jjp Biologics.
VAXiCAN's categories are Biotechnology Research
VAXiCAN's founding year is 2019
Top VAXiCAN Employees
-
Krzysztof Łepek
Founder And Coo At Vaxican Sp. Z O.O.
Gdańsk, Pomorskie, Poland, Poland1biotech.ug.gda.pl -
Dorota Lesiak
Office Manager
Gdańsk, Pomorskie, Poland, Poland -
-
Łukasz Rąbalski
Ceo At Vaxican, Asst. Prof. At…
Gdańsk, Pomorskie, Poland, Poland1gmail.com
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.